Table 2 |
||||
|
Incidence of tumours in irradiated (BALB/cHeA × MSM/Ms) F1 female mice that were heterozygously deficient for p53 and/or Atm genes |
||||
|
Genotypes |
p53+/- |
p53+/+ |
||
|
|
||||
|
Atm+/- (n = 55) |
Atm+/+ (n = 61) |
Atm+/- (n = 47) |
Atm+/+ (n = 53) |
|
|
|
||||
|
Mammary carcinoma |
32 (58%)a* |
19 (31%) |
0 (0%) |
1 (2%) |
|
Lymphoma |
24 (44%)b |
29 (48%) |
26 (55%) |
22 (42%) |
|
Squamous cell carcinoma |
1 (2%) |
1 (2%) |
0 (0%) |
0 (0%) |
|
Histiocytic sarcoma |
1 (2%)c |
0 (0%) |
0 (0%) |
0 (0%) |
|
Basal cell carcinoma |
0 (0%) |
1 (2%) |
0 (0%) |
0 (0%) |
|
Granulocytic leukaemia |
0 (0%) |
1 (2%) |
0 (0%) |
0 (0%) |
|
Ovarian carcinoma |
0 (0%) |
1 (2%) |
0 (0%) |
0 (0%) |
|
Nonthymic lymphoma (NOS) |
0 (0%) |
1 (2%) |
3 (6%) |
0 (0%) |
|
Solid tumour (NOS) |
1 (2%)d |
1 (2%)e |
1 (2%) |
1 (2%) |
|
Number of mammary carcinomas/mousee |
52/55 (0.95)** |
28/61 (0.46) |
0/47 (0.00) |
1/53 (0.02) |
|
|
||||
|
aNumber of mice with tumours; percentage in parenthesis is the proportion of mice developing mammary carcinoma. bThree animals developed both lymphomas and mammary carcinoma. cOne animal developed both histiocytic sarcoma and mammary carcinoma. dTumour in abdomen. eTotal number of mammary carcinomas developing in mice with given genotypes/number of mice examined; numbers in parentheses are average numbers of tumours per mouse. *The proportion of mice developing tumours is significantly greater than that in p53+/- Atm+/+ mice (P = 0.0034 by c2 test). **The average number of tumours/mouse is significantly greater than that in p53+/- Atm+/+ mice (P = 0.0052 by Mann–Whitney U-test). NOS, not otherwise specified. |
||||
|
Umesako et al. Breast Cancer Res 2005 7:R164 doi:10.1186/bcr968 |
||||
